As India braces for colossal vaccination campaign, one drugmaker has been waiting in the wings

The billionaire CEO of his family-run company, the Serum Institute of India, decided early on in the COVID-19 pandemic to bet big and go all out — striking a deal with Oxford-AstraZeneca to mass produce millions of doses of one of the more promising vaccine candidates before it was even close to being tested and approved.